RHYTHM BIOSCIENCES LIMITED — Capital/Financing Update 2021

Jul 27, 2021

Market Announcement

==> picture [33 x 50] intentionally omitted <==

28 July 2021

==> picture [451 x 5] intentionally omitted <==

Rhythm Biosciences Limited (ASX: RHY) – Trading Halt

Description

The securities of Rhythm Biosciences Limited (‘RHY’) will be placed in trading halt at the request of RHY, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 30 July 2021 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

28 July 2021 ASX Limited

==> picture [211 x 73] intentionally omitted <==

Request for Trading Halt

28 July 2021

Melissa Kostopoulos Listing Compliance - Melbourne ASX Compliance Pty Ltd 525 Collins Street North Tower Level 4 MELBOURNE VIC 3000

Dear Melissa

Pursuant to ASX Listing Rule 17.1, Rhythm Biosciences Limited ACN 619 459 335 (Company) requests that the ASX grants a trading halt with respect to the Company's shares.

The trading halt is requested pending an announcement to be made by the Company to the market in connection with considering, planning and executing a material capital raising (“purpose”).

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market for the stated purpose.

2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Friday 30 July 2021, or when the announcement regarding the purpose is released to the market.

3. The Company expects to make the announcement to the market before the commencement of normal trading on Friday 30 July 2021.

4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Released with the authority of the Board.

Yours sincerely

==> picture [94 x 51] intentionally omitted <==

Mr Adrien Wing Company Secretary

Rhythm Biosciences ACN: 619 459 335 ASX: RHY

Issued Capital 202,170,811 Shares 10,370,000 Options

Directors

Australian Registered Office Level 2, 480 Collins Street Melbourne VIC 3000 www.rhythmbio.com

Otto Buttula – Chairman of the Board Trevor John Lockett – Executive Director Louis James Panaccio – Non-Executive Director Eduardo Vom – Non-Executive Director